Furthermore, NSC617145 treatment led to elevated DNA damage accumulation in BRCA2−/− tumor cells as demonstrated by increased immunohistochemical staining for γH2AX (Fig. 8d) and 53BP1 (Fig. 8e) in tissue sections of BRCA2−/− tumors compared to WT tumors. This evidence concerns the gene TP53BP1 and neoplasm.